LF
LFCR.US Lifecore Biomedical Inc.
- Market cap
- USD 243M
- P/E
- -
- P/B
- 197.99x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Aug 2026.
Is LFCR.US undervalued?
Graham numberThe Graham number of Lifecore Biomedical Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lifecore Biomedical Inc. fundamental analysis
No fundamental analysis for Lifecore Biomedical Inc. yet.
Lifecore Biomedical Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lifecore Biomedical Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company a…
Full company profileLifecore Biomedical Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lifecore Biomedical Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 532M | 524M | 558M | 160M | 101M | 186M | 111M | 128M | 129M | 129M | 101M |
| Gross Profit | 83.2M | 78.3M | 81.0M | 39.4M | 38.9M | 50.4M | 39.1M | 41.9M | 40.3M | 40.6M | 27.3M |
| Operating Income | 15.5M | 11.8M | -8.01M | -25.9M | -8.82M | -3.60M | -11.8M | -8.84M | -17.2M | -1.26M | -3.58M |
| EBITDA | 26.7M | 26.0M | 24.1M | -7.16M | -987K | -68.0M | 12.8M | 35.6M | -8.81M | 5.98M | -128M |
| Net Income | 10.6M | 24.8M | 2.12M | -38.2M | -32.3M | -97.4M | -117M | 12.0M | -38.7M | -30.8M | -160M |
| EPS | 0.38 | 0.89 | 0.07 | -1.31 | -1.10 | -3.30 | -3.96 | 0.33 | -1.11 | -0.82 | -4.24 |
| Balance Sheet | |||||||||||
| Total Assets | 358M | 405M | 519M | 541M | 503M | 295M | 275M | 254M | 239M | 232M | 228M |
| Total Liabilities | 130M | 152M | 249M | 310M | 300M | 187M | 187M | 243M | 238M | 246M | 251M |
| Shareholders' Equity | 227M | 253M | 270M | 231M | 203M | 108M | 87.8M | 11.3M | 1.34M | -14.2M | -73.4M |
| Cash & Short-term Investments | 5.41M | 2.90M | 1.08M | 360K | 1.16M | 1.64M | 991K | 8.46M | 8.27M | 17.5M | 23.0M |
| Total Debt | 54.0M | 72.9M | 153M | 221M | 216M | 153M | 248M | 134M | 131M | 143M | 223M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 29.3M | 19.8M | 16.0M | -17.0M | 16.5M | -24.4M | -22.6M | 257K | -206K | 12.6M | 37.8M |
| Capital Expenditure | 22.6M | 33.6M | 44.7M | 26.7M | 25.2M | 28.1M | 29.9M | 18.4M | 13.4M | 6.34M | 10.2M |
| Free Cash Flow | 6.74M | -13.8M | -28.7M | -43.7M | -8.75M | -52.5M | -52.5M | -18.1M | -13.6M | 6.23M | 27.7M |
| Ratios | |||||||||||
| ROE | 4.7% | 9.8% | 0.8% | -16.5% | -15.9% | -90.3% | -132.9% | 106.2% | -2,898.0% | - | - |
| ROA | 3.0% | 6.1% | 0.4% | -7.1% | -6.4% | -33.0% | -42.5% | 4.7% | -16.2% | -13.3% | -70.2% |
| Net Profit Margin | 2.0% | 4.7% | 0.4% | -23.9% | -32.0% | -52.4% | -104.9% | 9.4% | -30.0% | -23.8% | -158.3% |
| Debt to Equity | 0.24x | 0.29x | 0.56x | 0.96x | 1.06x | 1.42x | 2.82x | 11.81x | 97.92x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lifecore Biomedical Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | USD 3.08M | 0.08 | 25.6% |
| 2023 | USD 274K | 0.01 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 212K | 0.01 | - |
| 2019 | USD 700K | 0.02 | 33.0% |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Lifecore Biomedical Inc.
- Insiders 3.19%
- Institutions 71.80%
- Public & others 25.01%
- Shares outstanding 37.9M
- Free float 19.6M
Top funds holding LFCR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 822K | 2.17% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 713K | 1.88% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 305K | 0.81% | +0.84% | Aug 2026 |
| iShares Russell 2000 Value ETF | 274K | 0.72% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 179K | 0.47% | -8.19% | Sep 2026 |
| Vanguard Russell 2000 ETF | 165K | 0.44% | +1.03% | Sep 2026 |
| Allspring Small Company Val | 132K | 0.35% | 0.00% | Sep 2026 |
| Allspring Small Company Value A | 118K | 0.31% | -0.12% | Sep 2026 |
| iShares Micro-Cap ETF | 86.2K | 0.23% | 0.00% | Oct 2026 |
| 1290 VT GAMCO Small Company Value IB | 78.0K | 0.21% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 69.8K | 0.18% | -0.05% | Sep 2026 |
| Schwab Small Cap Index | 69.1K | 0.18% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 56.2K | 0.15% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 46.9K | 0.12% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 43.4K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Small Cap Value Index | 38.6K | 0.10% | +5.06% | Aug 2026 |
| Nuveen Small Cap Blend Idx R6 | 35.9K | 0.09% | 0.00% | Sep 2026 |
Top institutions holding LFCR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Wynnefield Capital Inc | 4.70M | 12.41% | 0.00% | Jun 2026 |
| Legion Partners Asset Management, LLC | 4.46M | 11.77% | 0.00% | Jun 2026 |
| Greenhaven Road Investment Management, L.P. | 3.19M | 8.42% | -9.80% | Jun 2026 |
| 325 Capital LLC | 2.90M | 7.64% | +33.92% | Jun 2026 |
| BlackRock Inc | 2.01M | 5.31% | +7.23% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.29M | 3.40% | -0.12% | Jun 2026 |
| Geode Capital Management, LLC | 856K | 2.26% | +4.96% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 769K | 2.03% | +0.60% | Jun 2026 |
| State Street Corp | 668K | 1.76% | +4.05% | Jun 2026 |
| Quinn Opportunity Partners LLC | 539K | 1.42% | +18.95% | Sep 2026 |
| DCF Advisers, LLC | 425K | 1.12% | 0.00% | Jun 2026 |
| Wittenberg Investment Management Inc | 314K | 0.83% | +4.04% | Jun 2026 |
| Northern Trust Corp | 254K | 0.67% | +11.25% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 240K | 0.63% | +1.21% | Jun 2026 |
| LPL Financial Corp | 207K | 0.55% | -0.24% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 189K | 0.50% | +14.90% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 177K | 0.47% | +204.13% | Jun 2026 |
| Renaissance Technologies Corp | 163K | 0.43% | +55.45% | Sep 2026 |
| Tocqueville Asset Management L.P. | 152K | 0.40% | 0.00% | Jun 2026 |
| Millennium Management LLC | 133K | 0.35% | -15.18% | Jun 2026 |
Lifecore Biomedical Inc. company profile
- Company name
- Lifecore Biomedical Inc.
- Ticker
- LFCR.US
- Exchange
- USA Stocks
- Listed since
- Feb 15, 1996
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 382
- Fiscal year end
- May
- Address
- 3515 Lyman Boulevard, Chaska, MN, United States, 55318
- Phone
- 952 368 4300
- Website
- lifecore.com
About Lifecore Biomedical Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Lifecore Biomedical Inc. management
8- Mr. Paul JosephsPresident, CEO & Director · born 1965
- Mr. Ryan D. Lake CPAExecutive VP & CFO · born 1977
- Mr. Thomas D. SalusChief Legal & Administration Officer and Corporate Secretary · born 1969
- Mr. Thomas GuldagerVice President of Operations
- Mr. Aaron PerlitshDirector of Internal Audit & Chief Compliance Officer
- Ms. Jackie Q. KleckerExecutive Vice President of Quality & Development Services
- Mr. Mark DaFonsecaChief Commercial Officer
- Mr. Parker K. JavidVice President · born 1969